MedTrace Logo

Etanercept and Vascular Function in Psoriasis

NCT01989689 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2014-12-19

Study results available
· View outcomes & findings →

Summary

The investigators plan to measure the health of the vascular system of subjects taking Etanercept for the treatment of plaque psoriasis.

Conditions

Interventions

DRUG

Etanercept

Etanercept 50mg twice weekly

DRUG

Placebo

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Emory University

    lead OTHER

Principal Investigators

  • Arshed A Quyyumi, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01989689 on ClinicalTrials.gov